Business
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols
About this update from Biofrontera Inc.
[{"type":"text","content":"Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance to Biofrontera Bioscience GmbH for patent application No. 12/520,759 (the ’759 patent), titled “Nanoemulsion Formulation with Improved Stability and Cell Penetration.” Biofrontera Inc. has an exclusive license to market and sell Ameluz®, an FDA-approved drug utilizing the technology covered by the patent, in the U.S. The ’759 patent relates to the compositions of Biofrontera’s nanoemulsions and an active agent (such as in Ameluz®) and the preparation of the nanoemulsions or compositions, and describes its use in the treatment of dermatological, virus-associated and cell proliferation diseases, as well as in cosmetics. Biofrontera’s compositions of nanoemulsions overcome the disadvantages of other nanoemulsion formulations through a reduced particle size that contributes to improved stability, better penetration into cells and tissues and lower production costs. The notice of allowance precedes the granting of the patent by the USPTO, which typically follows soon after the patent holder pays the required fee. “This new patent will further protect Biofrontera’s growing position in the dermatology market and our continued investment in the market. Compound-of-matter patents provide the strongest protection of all patent types. Our license agreement covers all combinations of the patented nanoemulsion technology with aminolevulinic acid, the active ingredient in Ameluz®. Together with Biofrontera Bioscience we are now even more strongly positioned to broaden the use of photodynamic therapy (PDT) in dermatology,” stated Hermann Lübbert, Executive Chairman of Biofrontera Inc. “Utilizing nanoemulsion technology can help elevate PDT to the leading choice in treating actinic keratosis (AK). When formulated together with aminolevulinic acid, our nanoemulsion has demonstrated increased efficiency in cell uptake. This improves selectivity and also shortens the penetration period, or the time between applying th...